Merck KGaA Returns PKU Drugs To BioMarin To Focus On Cancer

Merck KGaA is returning to BioMarin Pharmaceutical Inc the rights to the Kuvan (sapropterin) drug against rare genetic disorder PKU as the diversified German group seeks to exit non-core areas to focus on cancer, immunology and neurology.

Merck KGaA is returning to BioMarin Pharmaceutical Inc the rights to the Kuvan (sapropterin) drug against rare genetic disorder PKU as the diversified German group seeks to exit non-core areas to focus on cancer, immunology and neurology.

More from Anticancer

More from Therapy Areas

Cerevance To Focus On Parkinson’s Adjunctive Therapy After Phase II Miss

 
• By 

After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.

Baxdrostat, AstraZeneca’s Next Big CVRM Bet

 
• By 

The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.

Merck’s Winrevair Slashes Morbidity-Mortality Risk For PAH Patients

 

The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.